Affiliation:
1. Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, Louisiana
Abstract
ABSTRACT
The purpose of this study was to quantitatively compare, in a rabbit keratitis model, the levels of effectiveness of moxifloxacin, levofloxacin, and ciprofloxacin for the treatment of
Staphylococcus aureus
isolates of diverse antibiotic susceptibilities. Rabbit eyes were intrastromally injected with approximately 100 CFU of methicillin-sensitive or methicillin-resistant
S. aureus
(MSSA or MRSA, respectively) organisms that were either sensitive or resistant to ofloxacin. One drop of moxifloxacin (0.5%), levofloxacin (0.5%), or ciprofloxacin (0.3%) was topically applied hourly from 4 to 9 (early) or 10 to 15 (late) h postinfection. At 1 h after cessation of therapy, the corneas were harvested, and the number of CFU per cornea was determined. For the ofloxacin-sensitive strains, early treatment of MSSA or MRSA with moxifloxacin, levofloxacin, or ciprofloxacin produced approximately a 5-log decrease in CFU per cornea relative to that in untreated eyes (
P
≤ 0.0001). For late therapy of ofloxacin-sensitive strains, moxifloxacin, levofloxacin, and ciprofloxacin produced approximately 5-, 4-, and 2- to 3-log reductions in CFU per cornea, respectively (
P
≤ 0.0001). Early treatment of the ofloxacin-resistant strains with either moxifloxacin or levofloxacin produced a ≥4-log or ≥3-log decrease, respectively, in the MSSA or MRSA strains (
P
≤ 0.0001), whereas ciprofloxacin treatment produced a 1-log decrease in CFU per cornea relative to that in untreated eyes (
P
= 0.1540). For late treatment of ofloxacin-resistant strains, levofloxacin and ciprofloxacin failed to significantly reduce the number of CFU per cornea (
P
≥ 0.3627), whereas moxifloxacin produced a significant reduction in CFU per cornea of approximately 1 log (
P
≤ 0.0194). Therefore, for three of the four treatments tested, moxifloxacin demonstrated greater effectiveness than either levofloxacin or ciprofloxacin.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference27 articles.
1. Adams, D. E., E. M. Shekhtman, E. L. Zechiedrich, M. B. Schmidt, and N. R. Cozzarelli. 1992. The role of topoisomerase IV in partitioning bacterial replicons and the structure of catenated intermediates in DNA replication. Cell71:277-288.
2. Shifting trends in bacterial keratitis in South Florida and emerging resistance to fluoroquinolones
3. Biedenbach, D. J., and R. N. Jones. 1996. The comparative antimicrobial activity of levofloxacin tested against 350 clinical isolates of streptococci. Diagn. Microbiol. Infect. Dis.25:47-51.
4. Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases
5. Callegan, M. C., J. A. Hobden, J. M. Hill, M. S. Insler, and R. J. O'Callaghan. 1992. Topical antibiotic therapy for the treatment of experimental Staphylococcus aureus keratitis. Investig. Ophthalmol. Vis. Sci.33:3017-3023.
Cited by
57 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献